MDT-AP-2296
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- sex
- F
- new_clusters
- C5
- umap1_2d
- 5.964991187
- umap2_2d
- 5.608300067
- umap1_3d
- 2.146466025
- umap2_3d
- -0.025594502
- umap3_3d
- -1.481698866
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.310
- KRAS_SIGNALING_DN+0.300
- INFLAMMATORY_RESPONSE+0.240
- MYOGENESIS+0.190
- COAGULATION+0.180
- COMPLEMENT+0.180
- INTERFERON_ALPHA_RESPONSE+0.180
- INTERFERON_GAMMA_RESPONSE+0.150
- KRAS_SIGNALING_UP+0.150
- IL6_JAK_STAT3_SIGNALING+0.140
Top 10 suppressed
- E2F_TARGETS-0.590
- G2M_CHECKPOINT-0.580
- MYC_TARGETS_V2-0.540
- UNFOLDED_PROTEIN_RESPONSE-0.510
- MITOTIC_SPINDLE-0.500
- MTORC1_SIGNALING-0.480
- MYC_TARGETS_V1-0.480
- PROTEIN_SECRETION-0.440
- DNA_REPAIR-0.400
- PI3K_AKT_MTOR_SIGNALING-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8942994 | — | — | 0.915 |
| 2 | MNG450 | — | — | 0.913 |
| 3 | TCGA-97-A4M2-01A-12R-A24X-07 | — | cohortA1 | 0.911 |
| 4 | ee0e68bf-7fa0-4edc-a9df-30a63c2db34a | — | — | 0.908 |
| 5 | TCGA-55-7728-01A-11R-2187-07 | — | cohortA1 | 0.907 |
| 6 | BS_94MT16N2 | pilocytic astrocytoma | — | 0.904 |
| 7 | MNG1148 | — | — | 0.903 |
| 8 | TCGA-93-A4JO-01A-21R-A24X-07 | — | cohortA1 | 0.903 |
| 9 | MNG882 | — | — | 0.902 |
| 10 | SRR1313642 | GTEX | — | 0.899 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.310 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.240 | Idelalisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| COMPLEMENT | 0.180 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.180 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.150 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.150 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.140 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.110 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.010 | Idelalisib | — uncovered |